Prevalence and Epidemiological and Clinical Features of Bacterial Infections in a Large Cohort of Patients Hospitalized for COVID-19 in Southern Italy: A Multicenter Study.
COVID-19
PCT
antimicrobial prescriptions
bacterial infections
superinfections
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
29 Jun 2023
29 Jun 2023
Historique:
received:
03
06
2023
revised:
22
06
2023
accepted:
26
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The aim of this study was to evaluate the prevalence of bacterial infections and antimicrobial prescriptions in a large cohort of COVID-19 patients and to identify the independent predictors of infection and antibiotic prescription. All consecutive patients hospitalized for COVID-19 from March 2020 to May 2021 at 1 of the 17 centers participating in the study were included. All subjects showing a clinical presentation consistent with a bacterial infection with microbiological confirmation (documented infection), and/or a procalcitonin value >1 ng/mL (suspected infection) were considered as having a coinfection (if present at admission) or a superinfection (if acquired after at least 48 h of hospital stay). During the study period, of the 1993 patients, 42 (2.1%) presented with a microbiologically documented infection, including 17 coinfections and 25 superinfections, and 267 (13.2%) a suspected infection. A total of 478 subjects (24.5%) received an antibacterial treatment other than macrolides. No independent predictors of confirmed or suspected bacterial infection were identified. On the contrary, being hospitalized during the second wave of the pandemic (OR 1.35, 95% CI 1.18-1.97, Our study reported a high rate of antimicrobial prescriptions despite a limited number of documented or suspected bacterial infections among the large cohort of hospitalized COVID-19 patients.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate the prevalence of bacterial infections and antimicrobial prescriptions in a large cohort of COVID-19 patients and to identify the independent predictors of infection and antibiotic prescription.
METHODS
METHODS
All consecutive patients hospitalized for COVID-19 from March 2020 to May 2021 at 1 of the 17 centers participating in the study were included. All subjects showing a clinical presentation consistent with a bacterial infection with microbiological confirmation (documented infection), and/or a procalcitonin value >1 ng/mL (suspected infection) were considered as having a coinfection (if present at admission) or a superinfection (if acquired after at least 48 h of hospital stay).
RESULTS
RESULTS
During the study period, of the 1993 patients, 42 (2.1%) presented with a microbiologically documented infection, including 17 coinfections and 25 superinfections, and 267 (13.2%) a suspected infection. A total of 478 subjects (24.5%) received an antibacterial treatment other than macrolides. No independent predictors of confirmed or suspected bacterial infection were identified. On the contrary, being hospitalized during the second wave of the pandemic (OR 1.35, 95% CI 1.18-1.97,
CONCLUSIONS
CONCLUSIONS
Our study reported a high rate of antimicrobial prescriptions despite a limited number of documented or suspected bacterial infections among the large cohort of hospitalized COVID-19 patients.
Identifiants
pubmed: 37508220
pii: antibiotics12071124
doi: 10.3390/antibiotics12071124
pmc: PMC10376680
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Infect Dis. 2021 May 18;72(10):e533-e541
pubmed: 32820807
Int J Environ Res Public Health. 2022 Nov 30;19(23):
pubmed: 36498078
PLoS One. 2022 Jan 13;17(1):e0262342
pubmed: 35025929
Infect Control Hosp Epidemiol. 2022 Dec 23;:1-6
pubmed: 36562287
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2103-2109
pubmed: 33161221
Pathogens. 2022 Jun 06;11(6):
pubmed: 35745506
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0134121
pubmed: 34491806
Euro Surveill. 2020 Nov;25(45):
pubmed: 33183403
Crit Care. 2020 Oct 6;24(1):600
pubmed: 33023606
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Microbiol Infect. 2022 Jan;28(1):114-123
pubmed: 34537362
Crit Care. 2021 Jan 11;25(1):25
pubmed: 33430915
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
PLoS One. 2021 Jun 1;16(6):e0252441
pubmed: 34061888
Health Aff (Millwood). 2020 Nov;39(11):2010-2017
pubmed: 32970495
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Microbiol Infect. 2020 Jul;26(7):808-810
pubmed: 32360446
J Clin Med. 2021 Jan 07;10(2):
pubmed: 33430492
Intern Emerg Med. 2022 Aug;17(5):1405-1412
pubmed: 35277828
Clin Microbiol Infect. 2022 Apr;28(4):491-501
pubmed: 34843962
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
J Nephrol. 2022 Jan;35(1):69-85
pubmed: 35013985
J Pers Med. 2021 Mar 22;11(3):
pubmed: 33809873
Lancet Microbe. 2023 Apr;4(4):e236-e246
pubmed: 36868258